These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15848204)

  • 21. Synthesis and pharmacological evaluation of novel 1- and 8-substituted-3-furfuryl xanthines as adenosine receptor antagonists.
    Balo MC; Brea J; Caamaño O; Fernández F; García-Mera X; López C; Loza MI; Nieto MI; Rodríguez-Borges JE
    Bioorg Med Chem; 2009 Sep; 17(18):6755-60. PubMed ID: 19682912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.
    Michielan L; Bolcato C; Federico S; Cacciari B; Bacilieri M; Klotz KN; Kachler S; Pastorin G; Cardin R; Sperduti A; Spalluto G; Moro S
    Bioorg Med Chem; 2009 Jul; 17(14):5259-74. PubMed ID: 19501513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N9-benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: synthesis and structure-activity relationships at adenosine A1 and A2A receptors.
    Drabczyńska A; Müller CE; Karolak-Wojciechowska J; Schumacher B; Schiedel A; Yuzlenko O; Kieć-Kononowicz K
    Bioorg Med Chem; 2007 Jul; 15(14):5003-17. PubMed ID: 17499511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.
    Moro S; Braiuca P; Deflorian F; Ferrari C; Pastorin G; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
    J Med Chem; 2005 Jan; 48(1):152-62. PubMed ID: 15634009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.
    Yan L; Müller CE
    J Med Chem; 2004 Feb; 47(4):1031-43. PubMed ID: 14761205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
    Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists.
    Catarzi D; Colotta V; Varano F; Calabri FR; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Tralli A; Montopoli C; Moro S
    Bioorg Med Chem; 2005 Feb; 13(3):705-15. PubMed ID: 15653338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.
    Morizzo E; Capelli F; Lenzi O; Catarzi D; Varano F; Filacchioni G; Vincenzi F; Varani K; Borea PA; Colotta V; Moro S
    J Med Chem; 2007 Dec; 50(26):6596-606. PubMed ID: 18047262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.
    Tafi A; Bernardini C; Botta M; Corelli F; Andreini M; Martinelli A; Ortore G; Baraldi PG; Fruttarolo F; Borea PA; Tuccinardi T
    J Med Chem; 2006 Jul; 49(14):4085-97. PubMed ID: 16821770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
    Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
    Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists.
    Burbiel JC; Ghattas W; Küppers P; Köse M; Lacher S; Herzner AM; Kombu RS; Akkinepally RR; Hockemeyer J; Müller CE
    ChemMedChem; 2016 Oct; 11(20):2272-2286. PubMed ID: 27531666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.
    Carotti A; Cadavid MI; Centeno NB; Esteve C; Loza MI; Martinez A; Nieto R; Raviña E; Sanz F; Segarra V; Sotelo E; Stefanachi A; Vidal B
    J Med Chem; 2006 Jan; 49(1):282-99. PubMed ID: 16392813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological activity of tricyclic aryloimidazo-, pyrimido-, and diazepinopurinediones.
    Drabczyńska A; Müller CE; Lacher SK; Schumacher B; Karolak-Wojciechowska J; Nasal A; Kawczak P; Yuzlenko O; Pekala E; Kieć-Kononowicz K
    Bioorg Med Chem; 2006 Nov; 14(21):7258-81. PubMed ID: 16844379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, biological assays and QSAR studies of N-(9-benzyl-2-phenyl-8-azapurin-6-yl)-amides as ligands for A1 adenosine receptors.
    Giorgi I; Leonardi M; Pietra D; Biagi G; Borghini A; Massarelli I; Ciampi O; Bianucci AM
    Bioorg Med Chem; 2009 Mar; 17(5):1817-30. PubMed ID: 19230680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma.
    Okamura T; Kurogi Y; Hashimoto K; Sato S; Nishikawa H; Kiryu K; Nagao Y
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3775-9. PubMed ID: 15203160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3D-pharmacophore models for selective A2A and A2B adenosine receptor antagonists.
    Wei J; Wang S; Gao S; Dai X; Gao Q
    J Chem Inf Model; 2007; 47(2):613-25. PubMed ID: 17330954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands.
    Okamura T; Kurogi Y; Nishikawa H; Hashimoto K; Fujiwara H; Nagao Y
    J Med Chem; 2002 Aug; 45(17):3703-8. PubMed ID: 12166943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor.
    Michielan L; Bacilieri M; Schiesaro A; Bolcato C; Pastorin G; Spalluto G; Cacciari B; Klotz KN; Kaseda C; Moro S
    J Chem Inf Model; 2008 Feb; 48(2):350-63. PubMed ID: 18215030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and pharmacology of pyrido[2,3-d]pyrimidinediones bearing polar substituents as adenosine receptor antagonists.
    Bulicz J; Bertarelli DC; Baumert D; Fülle F; Müller CE; Heber D
    Bioorg Med Chem; 2006 Apr; 14(8):2837-49. PubMed ID: 16377196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.
    Fernández F; Caamaño O; Isabel Nieto M; López C; García-Mera X; Stefanachi A; Nicolotti O; Isabel Loza M; Brea J; Esteve C; Segarra V; Vidal B; Carotti A
    Bioorg Med Chem; 2009 May; 17(10):3618-29. PubMed ID: 19398343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.